Alterity Therapeutics Enters Sales Agreement

TL;DR

**Alterity just signed a sales agreement with JonesTrading, likely setting up a future capital raise.**

AI Summary

On February 15, 2024, Alterity Therapeutics Limited, a development stage enterprise, announced it entered into a Sales Agreement with JonesTrading Institutional S. This Form 6-K filing is being incorporated by reference into several of the company's existing Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417, 333-250076).

Why It Matters

The establishment of a Sales Agreement with an institutional broker typically provides a development-stage company like Alterity Therapeutics with a flexible mechanism to potentially raise capital. This access to capital is vital for funding ongoing operations and research in the pharmaceutical sector.

Risk Assessment

Risk Level: medium — While providing a potential avenue for capital, the Sales Agreement implies future sales of securities, which could dilute the ownership stake of current shareholders.

Key Players & Entities

• Alterity Therapeutics Limited (company) — Registrant
• JonesTrading Institutional S (company) — Sales Agreement counterparty

FAQ

Key Financial Figures

• $6,000,000 — ent relating to the offering of up to US$6,000,000 in ADSs with the Securities and Exchang

Filing Documents

• ea193745-6k_alterity.htm (6-K) — 14KB
• ea193745ex1-1_alterity.htm (EX-1.1) — 260KB
• ea193745ex5-1_alterity.htm (EX-5.1) — 15KB
• ex5-1_001.jpg (GRAPHIC) — 22KB
• ex5-1_002.jpg (GRAPHIC) — 31KB
• ex5-1_003.jpg (GRAPHIC) — 6KB
• 0001213900-24-014643.txt ( ) — 372KB

From the Filing

OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2024 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) Alterity Therapeutics Limited (a development stage enterprise) EXPLANATORY NOTE On February 15, 2024 the Company entered into a Sales Agreement, or the Sales Agreement, with JonesTrading Institutional Services LLC, or JonesTrading, under which the Company may issue and sell American Depositary Shares (the “ADSs”) from time to time pursuant to a Prospectus Supplement through JonesTrading acting as Agent. and conditions of the Sales Agreement, the Agent will use its commercially reasonable efforts to sell the ADSs from time to time, based upon the Company’s instructions. The Company has provided the Agent with customary indemnification rights and the Agent will be entitled to a commission at a fixed commission rate equal to 3.0% of the gross sales price per shares sold. Sales of the ADSs under the Sales Agreement may be made by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415 of the Securities Act Regulations. The Shares will be issued pursuant to the Company’s previously filed and effective Registration Statement on Form F-3 (File No. 333-274816). On October 2, 2023, the Company filed a base Prospectus (which became effective on October 5, 2023) and on February 15, 2024, the Company filed a Prospectus Supplement relating to the offering of up to US$6,000,000 in ADSs with the Securities and Exchange Commission. This Report shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the Shares or the ADSs in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such The opinion of the Company’s counsel regarding the validity of the Shares that will be issued pursuant to the Prospectus Supplement is filed herewith as Exhibit 5.1. 1 Exhibits 1.1 Sales Agreement dated February 15, 2024 between Alterity Therapeutics Limited and JonesTrading Institutional Services LLC 5.1 Opinion of QR Lawyers Pty Ltd. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Phillip Hains Phillip Hains Chief Financial Officer Date: February 15, 2024 3

View Full Filing

View this 6-K filing on SEC EDGAR